Across TCGA pan-cancer cohorts, FAM111B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM111B data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FAM111B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM111B expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where FAM111B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.194	0.625	<.001	96	view →
HNSC	DFS	Median	III,IV	0.840	0.638	.024	5	view →
LSCC	DFS	Quartile	All	0.867	0.562	.006	4	view →
LUAD	DFS	Tertile	All	0.388	0.840	.030	2	view →
CCRCC	DFS	Median	All	1.000	0.620	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: FAM111B tumor-vs-normal RNA expression · all FAM111B data types